Skip to main content
Equibles
BRGX logo

BRGX · Bioregenx, Inc.

Track BRGX — free

Use BRGX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.01 At close · Aug 28
Rebalance outlook locked
Going-concern doubt — flagged May 20, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern. As reflected in the accompanying financial statements, for the three months ended March 31, 2026, the Company incurred a net loss of $(26,415), generated cash from operations of $26,629 and had a stockholder's deficit of $4,533,316 as of that date. At March 31, 2026, the Company had cash on hand in the amount of $45,806. In addition, notes payable of $522,500 are in default. As a result, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed May 20, 2026
Market Cap
$7.77M
Shares
971.58M

BRGX metrics

52 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.01
Market cap
$7.77M

Price action

19 metrics
Price change (1W)
+33.3%
Price change (30D)
+14.3%
Price change (3M)
-2.4%
Price change (6M)
-33.3%
Price change (YTD)
-38.0%
Price change (1Y)
-9.1%
Trailing year
Price change (5Y)
-87.7%
52-week high
$0.03
52-week low
$0.01
Change from 52-week high
-68.0%
Change from 52-week low
+45.5%
Annualized volatility
457.7%
Beta
-0.3
RSI (14D)
50.4
Price vs SMA 50
-13.5%
Price vs SMA 200
-37.3%
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
971.58M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.4×
reciprocal yield 22.7%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
278.5
reciprocal yield 0.4%
Earnings yield
-16.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
275.8×
reciprocal yield 0.4%
EV / revenue historical average (5Y)
275.8×
reciprocal yield 0.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
81.9%
Operating margin
-62.4%
Trailing 12 months
Net margin
-73.8%
Gross profit (TTM)
$1.45M
Operating profit (TTM)
−$1.10M
Net income (TTM)
−$1.30M
Trailing 12 months
Diluted EPS (TTM)
$0.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
-17.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.77M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
+253.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-386.6%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
−$1.03M
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
-3.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$45,806
Total assets
$337,070
Total debt
$1.19M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$27,906
Capital expenditures (TTM)
$9,057
R&D (TTM)
$31,750
SG&A (TTM)
$1.81M
Stock compensation (TTM)
$6,782
R&D / revenue
—
Stock compensation / revenue
0.4%

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1593184 Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)